Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's disease

BACKGROUND: Ileocolonic expression of IL13RA2 has been identified as a predictive marker for nonresponsiveness to infliximab (IFX) in patients with Crohn's disease (CD). AIM: To validate the IL13RA2 biomarker, study its anti‐TNF specificity and get a better understanding of the underlying biolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstockt, Bram, Verstockt, Sare, Creyns, Brecht, Tops, Sophie, Van Assche, Gert, Gils, Ann, Ceuppens, Jan L., Vermeire, Séverine, Ferrante, Marc, Breynaert, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Mucosal Il13ra2 Expression and Response to Anti‐tnf in Crohn's Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849553/
https://www.ncbi.nlm.nih.gov/pubmed/30663072
http://dx.doi.org/10.1111/apt.15126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849553/
https://www.ncbi.nlm.nih.gov/pubmed/30663072
http://dx.doi.org/10.1111/apt.15126

Ejemplares similares